# 177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

> **NCT04188587** · PHASE2 · UNKNOWN · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** 177 Lu-PSMA-I&T

## Key facts

- **NCT ID:** NCT04188587
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-01
- **Primary completion:** 2020-08
- **Final completion:** 2020-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04188587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04188587, "177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04188587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*